Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Atreca Inc (BCEL)  
$0.09 0.00 (4.61%) as of 4:30 Mon 5/13


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 29,990,000
Market Cap: 2.83(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.062 - $1.22
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1 1 1 1
Total Buy Value $0 $0 $0 $0
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 1
Total Shares Sold 20,788 20,788 353,058 410,690
Total Sell Value $1,455 $1,455 $144,635 $250,581
Total People Sold 1 1 6 6
Total Sell Transactions 1 1 9 14
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 132
  Page 2 of 6  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Cross Herb Chief Financial Officer   •       –      –    2021-09-09 4 A $0.00 $0 D/D 42,200 42,200     -
   Serafini Tito Chief Strategy Officer   •       •      –    2021-09-09 4 A $0.00 $0 D/D 42,200 42,200     -
   Courtney Phillips General Counsel & Secretary   •       –      –    2021-09-09 4 A $0.00 $0 D/D 35,500 35,500     -
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2021-03-17 4 AS $16.73 $83,650 D/D (5,000) 0 -55%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2021-03-17 4 OE $4.56 $24,050 D/D 5,000 2,916     -
   Robinson William Hewitt Director   –       •      –    2021-03-15 4 AS $16.89 $84,450 D/D (5,000) 368,948 -58%     
   Serafini Tito Chief Strategy Officer   •       •      –    2021-03-11 4 AS $18.22 $183,130 I/I (10,000) 353,875 -54%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2021-02-17 4 AS $18.95 $94,752 D/D (5,000) 0 -52%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2021-02-17 4 OE $5.16 $25,800 D/D 5,000 5,000     -
   Robinson William Hewitt Director   –       •      –    2021-02-16 4 AS $19.07 $95,331 D/D (5,000) 373,948 -53%     
   Serafini Tito Chief Strategy Officer   •       •      –    2021-02-11 4 AS $18.93 $189,272 I/I (10,000) 363,875 -57%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2021-01-19 4 AS $15.21 $76,045 D/D (5,000) 0 -42%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2021-01-19 4 OE $5.16 $25,800 D/D 5,000 5,000     -
   Robinson William Hewitt Director   –       •      –    2021-01-14 4 AS $15.06 $34,011 D/D (2,259) 378,948 -45%     
   Robinson William Hewitt Director   –       •      –    2021-01-13 4 AS $15.05 $41,239 D/D (2,741) 381,207 -44%     
   Serafini Tito Chief Strategy Officer   •       •      –    2021-01-11 4 AS $15.02 $150,192 I/I (10,000) 373,875 -41%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2020-12-17 4 AS $16.61 $83,051 D/D (5,000) 0 -28%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2020-12-17 4 OE $4.56 $22,800 D/D 5,000 5,000     -
   Robinson William Hewitt Director   –       •      –    2020-12-14 4 AS $16.67 $83,369 D/D (5,000) 383,948 -26%     
   Serafini Tito Chief Strategy Officer   •       •      –    2020-12-11 4 AS $15.87 $158,735 I/I (10,000) 383,875 -25%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2020-11-27 4 AS $15.34 $48,719 D/D (3,175) 0 -22%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2020-11-27 4 OE $4.56 $14,478 D/D 3,175 3,175     -
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2020-11-17 4 AS $15.04 $27,448 D/D (1,825) 0 -4%     
   Greenberg Norman Michael Chief Scientific Officer   •       –      –    2020-11-17 4 OE $4.56 $8,322 D/D 1,825 1,825     -
   Serafini Tito Chief Strategy Officer   •       •      –    2020-11-16 4 AS $15.12 $133,784 I/I (8,847) 393,875 -7%     
  132 Records found
  1  2  3  4  5  6   
  Page 2 of 6
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us